688180:SSEShanghai Junshi Biosciences Co., Ltd. Class A Analysis

Shanghai Junshi Biosciences is trading at CNY 30.69, well below its 20‑day SMA (33.5) and 50‑day SMA (37.68), with a bearish MACD and RSI around 34.6 indicating near‑oversold conditions. Technical momentum is weak, and the stock faces high 30‑day volatility (≈41%) and a sizable debt‑to‑equity ratio (~98), while profitability metrics remain negative (operating margin –12.7%, net margin –24.3%).
However, the recent announcement that its Phase 3 toripalimab‑plus‑chemotherapy trial met primary endpoints could provide a catalyst for revenue growth, especially given a strong pipeline of oncology candidates. The balance of a solid cash position against high leverage and poor earnings suggests caution, with the upside hinging on successful regulatory approvals and commercial rollout.